Solta Medical Inc (SLTM), Keryx Biopharmaceuticals (KERX): Two Stocks to Buy on Merger Speculation

Page 1 of 2

Large healthcare companies are facing revenue declines due to expiring patents. These cash rich giants are increasingly investing in small biotechnology companies with promising candidates. Solta Medical Inc (NASDAQ:SLTM) and Keryx Biopharmaceuticals (NASDAQ:KERX) are good targets for Big Pharma players looking to diversify or expand patent portfolios.

Solta Medical Inc (NASDAQ:SLTM)

Solta Medical Inc (NASDAQ:SLTM)’s board is resisting an acquisition but it seems highly likely that activist shareholders will succeed. The shareholders have already rejected the Board’s attempts to double outstanding shares and reduce chances of acquisition. Keryx is getting ready to submit its first NDA next month and there is a high probability that it will get FDA approval for Zerenex.

Medical Equipment

Solta Medical Inc (NASDAQ:SLTM) is involved in design, development and commercialization of energy-based medical appliance and equipment. Its target market expands to Middle East, North America, Europe and Asia Pacific. Solta Medical Inc (NASDAQ:SLTM) brands include Fraxel, Thermage, Liposonix, Isolaz and CLARO. Over the years it has developed its own distribution network but also utilizes independent distributors and retail networks. Solta Medical Inc (NASDAQ:SLTM)’s customers include gynecologists, dermatologists, plastics surgeons and ophthalmologists.

The valuations of Solta Medical Inc (NASDAQ:SLTM) have been pretty stagnant in the last few years. During the last few quarters shares have fluctuated between $2 and $3. While the valuations have remained stagnant, Solta has shown a significant revenue growth. The company revenues have increased from $110 million (2010) to $144 million (2012), growing by nearly 31%. Despite the revenue growth, gross margins have remained stable at around 62%. However, this growth has not been reflected in the bottom-line due to an approximately 100% increase in SG&A expenses to $104 million.

In the recent past Solta has become an attractive acquisition target. The stagnant price and lack of dividends indicate that a profitable acquisition should be the right option. However, the board of Solta has been resisting any such attempts. According to Voce Capital, the company has been actively trying to thwart acquisition attempts by interested parties. In its last week’s letter to the board, Voce has demanded that the board should formulate a special committee to evaluate M&A. The firm has also criticized the board for shareholder dissatisfaction and intentionally refusing good bids for Solta. The board is already low on investor confidence as the shareholders have rejected the Board’s proposal to double the shares outstanding to 200 million.

There are a number of parties interested in Solta Medical. There have been rumors that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is interested in acquiring Solta. The company has already acquired a number of companies in the last year.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!